Last reviewed · How we verify
Standard Antibiotic Therapy
Standard antibiotic therapy works by inhibiting bacterial protein synthesis, cell wall formation, or nucleic acid replication to kill or stop the growth of susceptible bacteria.
Standard antibiotic therapy works by inhibiting bacterial protein synthesis, cell wall formation, or nucleic acid replication to kill or stop the growth of susceptible bacteria. Used for Bacterial infections (broad-spectrum, indication varies by specific antibiotic used).
At a glance
| Generic name | Standard Antibiotic Therapy |
|---|---|
| Also known as | Standard documented antibiotic therapy |
| Sponsor | Catholic University of the Sacred Heart |
| Drug class | Antibiotic (multiple classes) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Standard antibiotic therapy encompasses multiple classes of antibiotics (e.g., beta-lactams, aminoglycosides, fluoroquinolones, macrolides) that target different bacterial structures and processes. These drugs either bactericidal (kill bacteria directly) or bacteriostatic (prevent bacterial replication), allowing the immune system to clear the infection. The specific mechanism depends on the antibiotic class used.
Approved indications
- Bacterial infections (broad-spectrum, indication varies by specific antibiotic used)
Common side effects
- Gastrointestinal disturbance (nausea, diarrhea, vomiting)
- Allergic reaction (rash, urticaria)
- Photosensitivity
- Tendinopathy (fluoroquinolones)
- Clostridium difficile infection
Key clinical trials
- Topical Methylene Blue-Photodynamic Therapy (MB-PDT) for Burn Wound Infection (PHASE1, PHASE2)
- Durability of Three Monthly Loading Doses With Faricimab in Treatment-naïve Neovascular Age-related Macular Degeneration
- Intracalvariosseous Plus Intravenous Antibiotics for Moderate-to-Severe Bacterial Meningitis (NA)
- Acupuncture for Colorectal sUrgery Recovery Enhancement: A Randomized Controlled Trial Evaluating Gastrointestinal Functional Recovery After Minimally Invasive Resection (NA)
- Integrated Outpatient Treatment of Opioid Use Disorder and Severe Injection Related Infections (PHASE2)
- MP101 in Adults With Acute Pseudomonas Aeruginosa Pneumonia (PHASE1)
- Safety and Tolerability of Metformin in People With Tuberculosis (TB) and Human Immunodeficiency Virus (HIV) (PHASE2)
- Vitamin C for Acute Kidney Injury in ACLF With Septic Shock: A Randomized Controlled Trial (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Standard Antibiotic Therapy CI brief — competitive landscape report
- Standard Antibiotic Therapy updates RSS · CI watch RSS
- Catholic University of the Sacred Heart portfolio CI